Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Coming out ahead, maybe

    Partitioning HCV Coming out ahead, maybe A back-of-the-envelope analysis of plausible rebate scenarios under the exclusive HCV deal between AbbVie Inc. (NASDAQ:ABBV) and Express Scripts Holding Co. (NASDAQ:ESRX) …

    Published on 1/19/2015
  • Figure: HCV landgrab

    Partitioning HCV The battle between Gilead Sciences Inc. (NASDAQ:GILD) and AbbVie Inc. (NASDAQ:ABBV) to secure HCV lives for their new drugs has been mostly focused on patients with genotype 1 infection who are …

    Published on 1/19/2015
  • Buyside view XXIII: Milestones galore

    2015 sees investors focus on big launches, cancer combos, NASH and gene therapy

    In 2015 investors are focused on big product launches, and data for cancer immunotherapy combos, NASH and gene therapy.

    Published on 1/12/2015
  • Table: 2015 milestones

    Milestones galore 2015 milestones Selected products with Phase III or regulatory milestones expected in 2015. Products up for approval this year are listed in "Approval Watch," see page 12. (A) Being acquired by …

    Published on 1/12/2015
  • Table: Approval watch

    Milestones galore Approval watch Selected products up for approval in 2015. (A) Being acquired by Merck & Co. Inc. (NYSE:MRK); Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event …

    Published on 1/12/2015
  • Table: New products to watch

    Milestones galore New products to watch Selected drugs that received regulatory approval in 2014. (A) Prior approvals in parentheses; (B) Being acquired by Merck & Co. Inc. (NYSE:MRK); Source: BCIQ: BioCentury …

    Published on 1/12/2015
  • Table: Post-launch report

    Milestones galore Post-launch report Three products that were first approved in 2013 have already recorded 2014 sales over $1 billion each. Two of them are oral HCV drugs — Sovaldi sofosbuvir from Gilead Sciences …

    Published on 1/12/2015
  • Table: Top biotech products

    Milestones galore Top biotech products At least 28 drugs developed and marketed by biotechs are expected to have more than $1 billion in 2014 sales. Antivirals from Gilead Sciences Inc. (NASDAQ:GILD) account for …

    Published on 1/12/2015
  • Figure: London vs. Europe

    Grow early, grow often London vs. Europe Both the BioCentury Europe and the BioCentury London indexes ended the year up more than 16%. The BC Europe posted a 24% gain, with advancers beating decliners 12-7. The …

    Published on 1/5/2015
  • Figure: Results by market cap

    Grow early, grow often Results by market cap The top market cap tier — companies valued above $5 billion — outperformed all other market cap segments in 2014, gaining 32% on the year. Of the 31 companies in the …

    Published on 1/5/2015
  • Table: 4Q approvals and setbacks

    Grow early, grow often 4Q approvals Selected fourth quarter approvals. (A) Cubist Pharmaceuticals Inc. (NASDAQ:CBST) is being acquired by Merck & Co. Inc. (NYSE:MRK) Company Approval AbbVie Inc. (NYSE:ABBV)/…

    Published on 1/5/2015
  • Table: Index performance

    Grow early, grow often Index performance The BioCentury 100, NYSE Arca Biotechnology (BTK) and NASDAQ Biotechnology (NBI) indices all ended the year well ahead of the general market benchmarks. The BC100 lagged …

    Published on 1/5/2015
  • Table: Restructuring watch

    Grow early, grow often Restructuring watch At least two companies reported workforce reductions in the fourth quarter compared to at least 13 in the same period last year. Tied with 1Q14, this is the smallest …

    Published on 1/5/2015
  • 2015 Financial Markets Preview: Show me in 2015

    How buysiders expect maturing sector to deliver growth in 2015

    Buysiders expect 2015 to be driven by mature large caps while follow-ons will be open for small caps that deliver on expectations.

    Published on 1/5/2015
  • Figure: Healthcare/biotech fund flows

    Show me in 2015 Healthcare/biotech fund flows More than $6 billion flowed into healthcare/biotech funds last quarter, bringing net fund flows to $18 billion for the year. The S&P 500 Health Care Index gained 7% …

    Published on 1/5/2015
  • Figure: M&A activity

    Show me in 2015 M&A activity The aggregate transaction value for M&A deals completed in 2014 reached a record $86 billion, beating the previous high of $80 billion in deals in 2011 and more than 2.6x the $32.5 …

    Published on 1/5/2015
  • Figure: Price-to-earnings: BT vs RX

    Grow early, grow often Price-to-earnings: BT vs RX The average biotech P/E ended the year at 22.4, about 1.3x the 17.7 average for big pharma. A year ago, biotech's P/E was 1.6x big pharma's multiple. The 13% …

    Published on 1/5/2015
  • Figure: Raised by market cap

    Show me in 2015 Raised by market cap In 2014, 467 public companies raised $45.5 billion vs. 401 companies that raised $31.2 billion in 2013. The increase was bolstered by large debt financings from a handful of …

    Published on 1/5/2015
  • Table: Follow-on performance

    Show me in 2015 Follow-on performance In 2014, $11 billion was raised via 150 follow-on offerings, above the $10 billion raised from 139 deals in 2013. The 2014 class is up a median of 14% from their postmoney …

    Published on 1/5/2015
  • Table: IPO performance

    Show me in 2015 IPO performance Twenty-three companies raised $2.1 billion in IPOs in 4Q14, bringing the total for 2014 to 112 companies that raised $9 billion. In 2013, 60 IPOs raised $3.9 billion. The median …

    Published on 1/5/2015
  • Table: IPO queue

    Show me in 2015 IPO queue Fourteen companies have announced plans to go public since the start of 4Q14, bringing the IPO queue to at least 31. Unless noted, companies are seeking to list on NASDAQ. (A) If proposed…

    Published on 1/5/2015
  • 4Q14 Stock Wrap-up: Grow early, grow often

    Winners, losers in biotech stock tiers in 4Q14

    Biotech stocks rose in all but the microcap tier in 4Q14, with strong showings by recent IPO companies.

    Published on 1/5/2015
  • Targeting access

    How ASCO, Palmetto propose to use cancer genomics to choose off-label therapies

    How ASCO and the Palmetto-backed Molecular Evidence Development Consortium propose to use cancer genomics to choose and study off-label therapies.

    Published on 12/22/2014
  • Table: TAPUR vs. MED-C

    Targeting access TAPUR vs. MED-C The American Society of Clinical Oncology and the Molecular Evidence Development Consortium (MED-C) are launching registries to collect evidence about biomarker-based off-label use…

    Published on 12/22/2014
  • Figure: Legal complexity

    Momenta moving on Legal complexity Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) had hoped its platform for characterizing complex molecules would create IP and know-how that would protect a portfolio of complex …

    Published on 12/15/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993